The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer

Drug resistance remains a barrier in the clinical treatment of ovarian cancer. Proteasomal and antioxidant activities play important roles in tumor drug resistance, and increasing evidence suggests the existence of an interaction between antioxidant and proteasomal activities. However, the mechanism...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oxidative medicine and cellular longevity 2020, Vol.2020 (2020), p.1-15
Hauptverfasser:	Su, Jing, Sun, Liankun, Jin, Yao, Luo, Haoge, Xu, Long, Fu, Jiaying, Lin, Nan, Deng, Xinyue, Liu, Yanan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antineoplastic Agents - pharmacology Antioxidants Antioxidants - metabolism Antioxidants - pharmacology Apoptosis Biotechnology Carcinoma, Ovarian Epithelial - drug therapy Cell cycle Cell Line, Tumor Chemotherapy Cisplatin - pharmacology Deoxyribonucleic acid DNA Drug resistance Enzymes Female Gene expression Gene Expression Regulation, Neoplastic - drug effects Homeostasis Humans Kinases Membranes Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovary - drug effects Ovary - metabolism Oxidative stress Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism Plasmids Proteins Reagents Signal transduction Signal Transduction - drug effects Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!